STERIS plc (STE) has been the subject of several investment firms' actions. Groupama Asset Management invested $1.16 million while Mirabella Financial Services LLP invested $2.45 million. Piper Sandler has reaffirmed its buy rating with a repeat target price of $300. Despite these positive investment movements, the stock has underperformed compared to its competitors, causing a 2.2% dip since the last earnings report. However, the company's growth in the healthcare sector could potentially help beat Q1 earnings. Furthermore, STERIS recently announced the expansion of their healthcare sterilization capabilities in global markets. Congress members Delaney and Cisneros also showed their faith by purchasing shares. The average rating from analysts currently stands at Moderate Buy, offering some reassurance. A potential rebound may be around the corner, with an increased stake by Intech Investment Management. With a quarterly dividend increased by 10.5% to $0.63/share, and strong Q3 earnings, the future might be fruitful for STERIS. Regardless of tariff challenges, STERIS has stuck to its 2026 profit targets, showing strength and resilience. Wall Street Zen recently upgraded their stock rating and it outperformed the health-care sector, serving as indicators of potential growth.
Steris Plc STE News Analytics from Thu, 29 May 2025 07:00:00 GMT to Sat, 21 Mar 2026 09:23:24 GMT -
Rating 5
- Innovation 4
- Information 3
- Rumor -6
